Neurogen Corp. has begun a Phase I trial for its leading drug candidate for treatment of obesity. The compound, NGD-4715, works as an antagonist at the melanin concentrating hormone receptor-1 (MCH1). William H. Koster, president and chief executive officer, said, “We are extremely pleased to be entering human testing exploring this promising new target. While the MCH1 mechanism has been a target of high interest in the pharmaceutical community, we believe most in the industry have encou...